Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB Trial of Relugolix and Enzalutamide as Neoadjuvant/ Adjuvant to Local-regional Treatment in Patients With High-risk Locally Advanced Prostate CAncer (RENAPCA)

NCT06130995 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT06130995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06130995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB Trial of Relugolix and Enzalutamide as Neoadjuvant/ Adjuvant to Local-regional Treatment in Patients With High-risk Locally Advanced Prostate CAncer (RENAPCA)
Lead sponsor
University of Oklahoma
Phase
Phase 1
Overall status
Recruiting
Start date
December 26, 2024
Completion date
January 31, 2030
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

androgen deprivation therapy, locally advanced prostate cancer